ArticleJournal of nanobiotechnology2025
PEGylated gas vesicles: a promising novel ultrasound contrast agent for diagnosis and guiding radiofrequency ablation of liver tumor.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- PLLA@PDA-DOX Nanobubbles for Ultrasound Imaging Combined Chemo-Photothermal Therapy.Biomolecules · 2026Article
- Exploring the applicability, combined strategies, and challenges of ablation in hematology based on its characteristics and immunomodulatory mechanisms.Clinical and experimental medicine · 2026Review
- Screening and Evaluation of Chassis Cells for Heterologous Biosynthesis of Gas Vesicles as Ultrasound Contrast Agents.Marine drugs · 2026Article
- αvβ3-targeted gas vesicles for ultrasound molecular imaging of tumors.Frontiers in bioengineering and biotechnology · 2026Article
- Ultrasound Imaging Properties of Heterologously Synthesized Gas Vesicles from Halophilic Archaeon.Nanomaterials (Basel, Switzerland) · 2025Article
- Ultrasound-responsive micro/nanobubbles based intelligent theranostic systems for precision tumor therapy.Journal of nanobiotechnology · 2025Review
- Early Detection of Vulnerable Plaques Using Targeted Biosynthetic Nanobubbles.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
Ultrasound contrast agents (UCAs) play an important role in diagnosis and the imaging-guided treatment of liver tumor in clinical settings. However, most commercially available UCAs are micro-sized and fabricated through a chemical synthesis route. Here, we developed a new class of biosynthesized nanoscale contrast agent (PEG-GVs) and comprehensively compared its physicochemical characteristics and imaging performance with commercial Sonovue and Sonazoid. Our results revealed PEG-GVs may produce more stable and durable contrast signals, contributing to their penetration beyond blood vessels and long-time retention in liver. Interestingly, we found that PEG-GVs did not exhibit a continuously enhanced accumulation in the liver tumor due to the EPR effect, but displayed a rapid regression. The long-time retention of PEG-GVs in normal liver tissue and rapid regression from liver tumor lead to distinct display of liver tumor boundaries, enabling the early diagnosis of small liver metastases and presenting advantages in guiding radiofrequency ablation of liver tumor. Moreover, we have also verified that PEG-GVs exhibit excellent imaging performance and biosafety in macaques. Our study provides new insights into the roles of PEG-GVs in liver tumor diagnosis and ablation guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.